EPIX
Income statement / Annual
Last year (2024), ESSA Pharma Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, ESSA Pharma Inc.'s net income was $0.00.
See ESSA Pharma Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
09/30/2024 |
09/30/2023 |
09/30/2022 |
09/30/2021 |
09/30/2020 |
09/30/2019 |
09/30/2018 |
09/30/2017 |
09/30/2016 |
09/30/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$217.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$118,491.00
|
$121,787.00
|
$109,464.00
|
$110,324.00
|
$0.00
|
$34,488.00
|
$46,145.00
|
$66,181.00
|
$0.00
|
| Gross Profit |
$0.00
|
-$118,491.00
|
-$121,787.00
|
-$109,464.00
|
-$110,324.00
|
$0.00
|
-$34,488.00
|
-$46,145.00
|
-$65,964.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-303.98
|
0
|
| Research and Development Expenses |
$21.21 M
|
$21.32 M
|
$24.42 M
|
$24.26 M
|
$12.15 M
|
$6.70 M
|
$4.87 M
|
$5.73 M
|
$13.06 M
|
$4.39 M
|
| General & Administrative Expenses |
$0.00
|
$10.79 M
|
$12.55 M
|
$12.78 M
|
$11.37 M
|
$5.47 M
|
$5.93 M
|
$5.14 M
|
$5.64 M
|
$3.70 M
|
| Selling & Marketing Expenses |
$0.00
|
$22,567.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$0.00
|
$10.81 M
|
$12.55 M
|
$12.78 M
|
$11.37 M
|
$5.47 M
|
$5.93 M
|
$5.14 M
|
$5.64 M
|
$3.70 M
|
| Other Expenses |
$0.00
|
$0.00
|
$1.74 M
|
$109,464.00
|
$515,000.00
|
$35,000.00
|
-$40,000.00
|
-$37,000.00
|
$79,000.00
|
$1.15 M
|
| Operating Expenses |
$21.21 M
|
$32.13 M
|
$36.96 M
|
$37.14 M
|
$23.52 M
|
$12.17 M
|
$10.80 M
|
$10.87 M
|
$18.70 M
|
$9.23 M
|
| Cost And Expenses |
$0.00
|
$32.13 M
|
$36.96 M
|
$37.14 M
|
$23.52 M
|
$12.17 M
|
$10.80 M
|
$10.87 M
|
$18.70 M
|
$9.23 M
|
| Interest Income |
$0.00
|
$5.55 M
|
$1.74 M
|
$234,997.00
|
$559,719.00
|
$26,251.00
|
$42,734.00
|
$0.00
|
$0.00
|
$618.25
|
| Interest Expense |
$0.00
|
$6,942.00
|
$14,000.00
|
$22,220.00
|
$618,000.00
|
$603,000.00
|
$912,000.00
|
$785,000.00
|
$938,000.00
|
$77,768.00
|
| Depreciation & Amortization |
$0.00
|
$118,491.00
|
$121,787.00
|
$109,464.00
|
$110,324.00
|
$18,297.00
|
$34,488.00
|
$46,145.00
|
$66,181.00
|
$39,099.00
|
| EBITDA |
$0.00 |
-$26.46 M |
-$35.08 M |
-$36.71 M |
-$23.01 M |
-$12.13 M |
-$10.77 M |
-$3.55 M |
-$18.67 M |
-$9.38 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-85829.49
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-90516.13
|
0
|
| Total Other Income/Expenses Net |
$0.00
|
$5.55 M
|
$1.74 M
|
$303,760.00
|
-$214,097.00
|
-$567,490.00
|
-$552,906.00
|
$11.68 M
|
$5.74 M
|
-$107,359.68
|
| Income Before Tax |
$0.00
|
-$26.58 M
|
-$35.22 M
|
-$36.84 M
|
-$23.73 M
|
-$10.40 M
|
-$11.60 M
|
-$4.38 M
|
-$12.99 M
|
-$8.57 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-59857.14
|
0
|
| Income Tax Expense |
$0.00
|
$1,600.00
|
-$112,000.00
|
-$34,349.00
|
-$289,000.00
|
$38,000.00
|
$27,000.00
|
$116,000.00
|
$151,000.00
|
$77,768.00
|
| Net Income |
$0.00
|
-$26.58 M
|
-$35.10 M
|
-$36.81 M
|
-$23.45 M
|
-$10.44 M
|
-$11.63 M
|
-$4.50 M
|
-$13.14 M
|
-$8.57 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-60553
|
0
|
| EPS |
-0.64 |
-0.6 |
-0.8 |
-0.96 |
-1.04 |
-1.24 |
-2.55 |
-3.09 |
-9.77 |
-9.34 |
| EPS Diluted |
-0.64 |
-0.6 |
-0.8 |
-0.96 |
-1.04 |
-1.24 |
-2.55 |
-3.09 |
-9.77 |
-9.34 |
| Weighted Average Shares Out |
$44.28 M
|
$44.09 M
|
$44.04 M
|
$38.48 M
|
$22.44 M
|
$8.43 M
|
$4.57 M
|
$1.45 M
|
$1.35 M
|
$917,650.00
|
| Weighted Average Shares Out Diluted |
$44.28 M
|
$44.09 M
|
$44.04 M
|
$38.48 M
|
$22.44 M
|
$8.43 M
|
$4.57 M
|
$1.45 M
|
$1.35 M
|
$917,650.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
